CA2101774A1 - Test and model for alzheimer's disease - Google Patents

Test and model for alzheimer's disease

Info

Publication number
CA2101774A1
CA2101774A1 CA002101774A CA2101774A CA2101774A1 CA 2101774 A1 CA2101774 A1 CA 2101774A1 CA 002101774 A CA002101774 A CA 002101774A CA 2101774 A CA2101774 A CA 2101774A CA 2101774 A1 CA2101774 A1 CA 2101774A1
Authority
CA
Canada
Prior art keywords
app770
allele
mutant
subject
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002101774A
Other languages
French (fr)
Other versions
CA2101774C (en
Inventor
John A. Hardy
Marie-Christine Chartier-Harlin
Alison M. Goate
Michael J. Owen
Michael J. Mullan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharmaceuticals LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26298303&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2101774(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB919101307A external-priority patent/GB9101307D0/en
Priority claimed from GB919118445A external-priority patent/GB9118445D0/en
Application filed by Individual filed Critical Individual
Priority to CA002372251A priority Critical patent/CA2372251A1/en
Publication of CA2101774A1 publication Critical patent/CA2101774A1/en
Application granted granted Critical
Publication of CA2101774C publication Critical patent/CA2101774C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Humanized animals, e.g. knockin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Abstract

Model systems of Alzheimer's disease comprise a DNA sequence encoding an amy-loid precursor protein (APP) isoform or fragment that has an amino acid substitution. The substituted amino acid may be other than valine at the amino acid position corresponding to amino acid residue position 717 of APP770. Methods of determining genetic predisposi-tion to Alzheimer's disease are also disclosed.

Claims (39)

1. An isolated polynucleotide comprising a nucleic acid sequence encoding a codon 717 mutant of human amyloid precursor protein 770 (APP770), or an isoform or fragment of APP770 having a mutant amino acid residue at the position encoded by codon 717.
2. An isolated polynucleotide of claim 1, wherein the amino acid at the position encoded by codon 717 is an isoleucine, glycine, or phenylalanine.
3. An isolated polynucleotide of claim 1, wherein the nucleic acid sequence is a cDNA.
4. A composition comprising a polynucleotide probe capable of specifically hybridizing to an amyloid precursor protein 770 (APP770) allele exhibiting a mutation at codon 717.
5. A composition of claim 4, wherein codon 717 of the mutant allele encodes an isoleucine, phenylalanine, or glycine.
6. A composition of claim 4, wherein the probe is labeled.
7. A composition of claim 4, wherein the probe comprises at least about 10 nucleotides spanning amino acid 717 of the APP770 allele.
8. A transgenic host comprising a nucleic acid segment encoding a position 717 mutant of human amyloid precursor protein 770 (APP770), or an APP770 isoform or fragment of APP770 having the mutation.
9. A host of claim 8, which is a primary or immortalized eukaryotic cell line.
10. A host of claim 8, which is a bacterium.
11. A host of claim 8, wherein the segment is integrated into the host genome.
12. A host of claim 8, which is a non-human animal having the DNA segment incorporated into its germline and which is capable of expressing the mutant APP770 protein.
13. A host of claim 12, wherein the mutant APP770 protein is the sole APP770 protein produced by the animal.
14. A transgenic non-human animal with germ cells or somatic cells comprising a heterologous gene encoding a position 717 mutant amyloid precursor protein 770 (APP770), which gene upon expression promotes neuropathological characteristics of Alzheimer's disease in the animal.
15. A cultured human primary or immortalized cell, comprising a nucleic acid segment encoding a position 717 mutant of human amyloid precursorprotein 770 (APP770), or an APP770 isoform or fragment of APP770 having the mutation.
16. A method of screening for an agent capable of treating Alzheimer's disease, comprising:
contacting a host of claim 8 with the agent; and monitoring expression or processing of proteins encoded by the mutant APP770 gene.
17. A diagnostic method for determining an inherited predisposition to Alzheimer's disease in a subject, comprising detecting in the subject the presence of an allele of amyloid precursor protein (APP), an isoformor fragment thereof, wherein said allele has a sequence polymorphism at a position corresponding to codon 717 of APP770.
18. A method of claim 17, wherein said sequence polymorphism is a nucleotide substitution, whereby an isoleucine or glycine is substituted atcodon 717 of APP770.
19. A method of claim 17, wherein said sequence polymorphism is a single nucleotide substitution.
20. A method according to claim 17, wherein the detecting step comprises sequencing a genomic DNA segment from chromosome 21 of the subject.
21. A method according to claim 17, wherein the detecting step comprises (i) mixing a nucleic acid sample from the subject with one or more polynucleotide probes capable of hybridizing selectively to an APP gene allele in a reaction and (ii) monitoring the reaction to determine the presence of the gene allele in the sample, thereby indicating whether the subject is at risk for Alzheimer's disease.
22. A method according to claim 20, wherein one probe is a polynucleotide comprising a sequence of at least about 10 nucleotides spanning codon 717 of an APP770.
23. A method according to claim 22, wherein the probes are oligonucleotides capable of priming polynucleotide synthesis in a polymerase chain reaction, wherein a reaction product comprises a sequence of at least 25 contiguous nucleotides from exon 17 of the APP gene.
24. A method according to claim 21, wherein at least one oligonucleotide specifically hybridizes to a sequence present in an intron or flanking region of an APP770 gene.
25. A method according to claim 21, wherein the monitoring step comprises analyzing sequencing gel reaction products from the PCR reaction.
26. A method according to claim 21, wherein the monitoring step comprises analyzing an autoradiograph of a BcII digest of reaction products fromthe PCR reaction.
27. A method according to claim 17, wherein the detecting step comprises (i) mixing in an immunological assay an APP770 or isoform protein sample from the subject with an antibody reagent specific for the allele and (ii) monitoring the assay to determine specific binding between the antibody reagent and the protein sample, thereby indicating whether the subject is at risk for Alzheimer's disease.
28. A method according to claim 27, wherein the antibody reagent is a monoclonal antibody specifically reactive with an antigenic determinant specific for an allele.
29. A method for genetic analysis of a human subject which comprises detecting the presence or absence of at least one polymorphism at codon 717 of an APP770 gene of an amyloid precursor protein (APP) gene in the subject.
30. A method according to claim 29, wherein the polymorphism is detected by digesting genomic DNA from the subject with at least one restriction endonuclease and hybridizing resulting fragments with a detecting probe
31. A composition comprising a polypeptide free from human proteins, comprising a core sequence:
Ile-Ala-Thr-Val-Ile-X-Ile-Thr-Leu- [SEQ ID NO:6]
wherein X is any of the twenty conventional amino acids except valine.
32. A transgenic nonhuman animal containing a polypeptide of claim 31.
33. A transgenic nonhuman animal of Claim 32, wherein the polypeptide is present in the brain.
34. An isolated polynucleotide, comprising a nucleic acid sequence encoding a mutant human APP allele that cosegregates with a genetic predisposition to Alzheimer's disease.
35. An isolated polypeptide of Claim 34, wherein said mutant human APP allele comprises a codon 717 mutant.
36. A method of determining a genetic predisposition of a subject to Alzheimer's disease, the method comprising detecting in the subject's DNA thepresence of an allele of a gene encoding amyloid precursor protein (APP).
37. A method as claimed in claim 36, wherein the step of detection is carried out on material removed from, and not returned to, the subject's body.
38. A method as claimed in claim 36 or 37, wherein the allele of the gene encodes a substitution mutant of APP.
39. A method as claimed in claim 38, wherein a single amino acid is substituted for another.
CA2101774A 1991-01-21 1992-01-21 Test and model for alzheimer's disease Expired - Lifetime CA2101774C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002372251A CA2372251A1 (en) 1991-01-21 1992-01-21 Test and model for alzheimer's disease

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB919101307A GB9101307D0 (en) 1991-01-21 1991-01-21 Test for alzheimers disease
GB9101307.8 1991-01-21
GB919118445A GB9118445D0 (en) 1991-08-28 1991-08-28 Test for alzheimer's disease
GB9118445.7 1991-08-28
PCT/GB1992/000123 WO1992013069A1 (en) 1991-01-21 1992-01-21 Test and model for alzheimer's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002372251A Division CA2372251A1 (en) 1991-01-21 1992-01-21 Test and model for alzheimer's disease

Publications (2)

Publication Number Publication Date
CA2101774A1 true CA2101774A1 (en) 1992-07-22
CA2101774C CA2101774C (en) 2011-01-04

Family

ID=26298303

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2101774A Expired - Lifetime CA2101774C (en) 1991-01-21 1992-01-21 Test and model for alzheimer's disease
CA002372251A Abandoned CA2372251A1 (en) 1991-01-21 1992-01-21 Test and model for alzheimer's disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002372251A Abandoned CA2372251A1 (en) 1991-01-21 1992-01-21 Test and model for alzheimer's disease

Country Status (10)

Country Link
US (3) US5877015A (en)
EP (2) EP0568575B2 (en)
JP (3) JP3510244B2 (en)
AT (2) ATE447016T1 (en)
AU (1) AU652997B2 (en)
CA (2) CA2101774C (en)
DE (3) DE971033T1 (en)
DK (2) DK0971033T3 (en)
ES (2) ES2335720T3 (en)
WO (1) WO1992013069A1 (en)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2335720T3 (en) 1991-01-21 2010-03-31 Elan Pharmaceuticals, Inc. TEST AND MODEL FOR ALZHEIMER'S DISEASE.
EP0613560B2 (en) * 1991-11-12 2006-06-21 Prana Biotechnology Ltd A method for assaying and treating alzheimer's disease
CA2126451A1 (en) * 1991-12-24 1993-07-08 Brett P. Monia Compositions and methods for modulating .beta.-amyloid
US5604131A (en) * 1992-01-07 1997-02-18 Athena Neurosciences, Inc. cDNA-genomic DNA hybrid sequence encoding APP770 containing a genomic DNA insert of the KI and OX-2 regions
EP0620849B1 (en) * 1992-01-07 2003-06-25 Elan Pharmaceuticals, Inc. Transgenic animal models for alzheimer's disease
US5455169A (en) * 1992-06-04 1995-10-03 Alzheimer's Institute Of America, Inc. Nucleic acids for diagnosing and modeling Alzheimer's disease
US6610493B1 (en) 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
US6328971B1 (en) * 1993-01-22 2001-12-11 Ludwig Institute For Cancer Research MAGE-1 derived nona peptides, and compositions thereof
EP1001019A1 (en) * 1993-10-27 2000-05-17 Athena Neurosciences, Inc. Transgenic animals harboring APP Allele having Swedish mutation
JPH07132033A (en) * 1993-11-12 1995-05-23 Hoechst Japan Ltd Transgenic animal for alzheimer's disease model
EP0742831B1 (en) 1994-01-27 2004-09-29 The Regents Of The University Of Minnesota Transgenic non-human mammals with progressive neurologic disease
US5877399A (en) * 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
JPH10504964A (en) * 1994-09-01 1998-05-19 メルク エンド カンパニー インコーポレーテッド Transgenic animals expressing familial human amyloid precursor protein
US6187992B1 (en) 1994-12-05 2001-02-13 Merck & Co., Inc. Transgenic mouse having a disrupted amyloid precursor protein gene
US5674681A (en) * 1994-12-06 1997-10-07 Rothenberg; Barry E. Methods to identify hemochromatosis
US6717031B2 (en) 1995-06-07 2004-04-06 Kate Dora Games Method for selecting a transgenic mouse model of alzheimer's disease
EP0832205A1 (en) * 1995-06-07 1998-04-01 Athena Neurosciences, Inc. Method for identifying alzheimer's disease therapeutics using transgenic animal models
AUPN649395A0 (en) * 1995-11-10 1995-12-07 Ramsay Health Care Pty Ltd A method for diagnosing alzheimer's disease
US7129061B1 (en) * 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
CA2183901A1 (en) * 1996-08-22 1998-02-23 Johanna E. Bergmann Targets for therapy and diagnosis of alzheimer's disease and down syndrome in humans
US6933331B2 (en) * 1998-05-22 2005-08-23 Nanoproducts Corporation Nanotechnology for drug delivery, contrast agents and biomedical implants
US5898094A (en) * 1996-10-21 1999-04-27 University Of South Florida Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes
ES2128265B1 (en) * 1997-06-04 2000-03-01 Euroespes S A GENETIC KIT FOR THE MOLECULAR CHARACTERIZATION OF ALZHEIMER'S DISEASE.
FR2770217B1 (en) * 1997-10-24 2001-12-07 Rhone Poulenc Rorer Sa PEPTIDES CAPABLE OF INHIBITING THE INTERACTION BETWEEN PRESENILINS AND THE PRECURSOR OF B-AMYLOID PEPTIDE AND / OR B-AMYLOID PEPTIDE
EP1025121B1 (en) * 1997-10-24 2011-08-24 Aventis Pharma S.A. Peptides capable of inhibiting the interaction between presenilins and the beta-amyloid peptide or its precursor
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
CN1300320C (en) 1998-09-24 2007-02-14 法玛西雅厄普约翰美国公司 Alzhimer's disease secretase
US6699671B1 (en) * 1998-09-24 2004-03-02 Pharmacia & Upjohn Company Alzheimer's disease secretase, APP substrates therefor, and uses therefor
US6844148B1 (en) 1998-09-24 2005-01-18 Pharmacia & Upjohn Company Alzheimer's disease secretase, APP substrates therefor, and uses therefor
US20040234976A1 (en) * 1998-09-24 2004-11-25 Gurney Mark E. Alzheimer's disease secretase, app substrates therefor, and uses therefor
US7456007B1 (en) 1998-12-31 2008-11-25 Elan Pharmaceuticals, Inc. β-secretase enzyme compositions and methods
US7115410B1 (en) * 1999-02-10 2006-10-03 Elan Pharmaceuticals, Inc. β-secretase enzyme compositions and methods
EP1165609A2 (en) 1999-02-10 2002-01-02 Elan Pharmaceuticals, Inc. Human beta-secretase enzyme, inhibitors and their compositions and uses
US6355425B1 (en) 1999-03-26 2002-03-12 Billups-Rothenberg, Inc. Mutations associated with iron disorders
US7056661B2 (en) * 1999-05-19 2006-06-06 Cornell Research Foundation, Inc. Method for sequencing nucleic acid molecules
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US20090162883A1 (en) * 1999-09-23 2009-06-25 Pharmacia & Upjohn Company Alzheimer's Disease Secretase, APP Substrates Thereof, and Uses Thereof
US7514408B1 (en) 1999-12-02 2009-04-07 Elan Pharmaceuticals, Inc. β-secretase enzyme compositions and methods
US6310048B1 (en) 1999-12-09 2001-10-30 St. Louis University Antisense modulation of amyloid beta protein expression
AU2914501A (en) * 1999-12-28 2001-07-09 Curagen Corporation Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
US6992081B2 (en) 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
ES2275675T3 (en) * 2000-03-23 2007-06-16 Elan Pharmaceuticals, Inc. COMPOUNDS AND METHODS TO TREAT ALZHEIMER'S DISEASE.
CA2410972A1 (en) 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
PE20020276A1 (en) 2000-06-30 2002-04-06 Elan Pharm Inc SUBSTITUTE AMINE COMPOUNDS AS ß-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER
EP1666452A2 (en) 2000-06-30 2006-06-07 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
US6846813B2 (en) * 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
US20030096864A1 (en) * 2000-06-30 2003-05-22 Fang Lawrence Y. Compounds to treat alzheimer's disease
EP1297132A1 (en) * 2000-07-06 2003-04-02 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. A novel app mutation associated with an unusual alzheimer's disease pathology
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (en) 2000-12-06 2002-07-02 Wyeth Corp HUMANIZED ANTIBODIES THAT RECOGNIZE THE AMYLOID PEPTIDE BETA
MXPA03011046A (en) * 2001-06-01 2004-06-25 Elan Pharm Inc Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases.
MXPA03011521A (en) 2001-06-13 2004-03-18 Elan Pharm Inc Aminediols as agents for the treatment of alzheimer's disease.
US6982264B2 (en) * 2001-06-27 2006-01-03 Elan Pharmaceuticals, Inc. Substituted alcohols useful in treatment of Alzheimer's disease
US20070213407A1 (en) * 2001-06-29 2007-09-13 Elan Pharmaceuticals And Pharmacia & Upjohn Company Llc Compounds to treat Alzheimer's disease
CA2453444A1 (en) * 2001-07-10 2003-01-23 Elan Pharmaceuticals, Inc. Diaminediols for the treatment of alzheimer's disease
JP2005505517A (en) * 2001-07-10 2005-02-24 イーラン ファーマスーティカルズ、インコーポレイテッド Aminediol for the treatment of Alzheimer's disease
US7297553B2 (en) * 2002-05-28 2007-11-20 Nanosphere, Inc. Method for attachment of silylated molecules to glass surfaces
BR0213139A (en) 2001-10-04 2004-08-10 Elan Pharm Inc Compound, method of treating or preventing disease and preparing a compound, use of a compound and pharmaceutical composition
IL161881A0 (en) * 2001-11-08 2005-11-20 Upjohn Co N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives
MXPA04004713A (en) * 2001-11-19 2005-08-16 Pharmacia & Up John Company Ll Amino diols useful in the treatment of alzheimer's disease.
US20040016008A1 (en) * 2002-01-07 2004-01-22 Brimijoin William Stephen Hybrid transgenic mouse with accelerated onsent of Alzheimer type amyloid plaques in brain
WO2003072041A2 (en) * 2002-02-27 2003-09-04 Merck & Co., Inc. Assays to monitor amyloid precursor protein processing
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2004058686A1 (en) * 2002-04-30 2004-07-15 Elan Pharmaceuticals, Inc. Hydroxypropyl amides for the treatment of alzheimer’s disease
UY27967A1 (en) * 2002-09-10 2004-05-31 Pfizer 2-HINDROXI-1,3-DIAMINOALCANE OIL
EP1565428A1 (en) * 2002-11-27 2005-08-24 Elan Pharmaceuticals, Inc. Substituted ureas and carbamates
ZA200505782B (en) 2003-02-01 2006-09-27 Neuralab Ltd Active immunization to generate antibodies to soluble A-beta
MXPA05011150A (en) * 2003-04-21 2005-12-14 Elan Pharm Inc (HETERO) ARYLAMIDE 2-HYDROXY-3-DIAMINOALKANES FOR USE IN THE TREATMENT OF ALZHEIMERaCOES DISEASE.
WO2004094413A1 (en) * 2003-04-21 2004-11-04 Elan Pharmaceuticals, Inc. Phenacyl 2-hydroxy-3-diaminoalkanes
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
US20050009110A1 (en) * 2003-07-08 2005-01-13 Xiao-Jia Chang Methods of producing antibodies for diagnostics and therapeutics
WO2005010039A1 (en) * 2003-07-31 2005-02-03 Pfizer Products Inc. Bsep polypeptide variants and uses thereof
US20060014790A1 (en) * 2004-01-21 2006-01-19 Varghese John Methods of treatment of amyloidosis using spirocyclohexane aspartyl-protease inhibitors
US20050239832A1 (en) * 2004-03-09 2005-10-27 Varghese John Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
CA2558036A1 (en) * 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamine aspartyl protease inhibitors
CA2558249A1 (en) * 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors
CA2558034A1 (en) * 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamine aspartyl protease inhibitors
US7544855B2 (en) * 2004-04-23 2009-06-09 Buck Institute Transgenic mouse whose genome comprises an APP having a mutation at amino acid 664
CA2567223A1 (en) * 2004-05-19 2005-11-24 Boehringer Ingelheim International Gmbh Treatment of diseases associated with altered level of amyloid beta peptides
WO2006010094A1 (en) * 2004-07-09 2006-01-26 Elan Pharmaceuticals, Inc. Oxime derivative hydroxyethylamine aspartyl-protease inhibitors
US7385085B2 (en) * 2004-07-09 2008-06-10 Elan Pharmaceuticals, Inc. Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
US8436006B2 (en) * 2004-08-06 2013-05-07 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8383637B2 (en) * 2004-08-06 2013-02-26 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8426429B2 (en) * 2004-08-06 2013-04-23 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
WO2006026533A2 (en) * 2004-08-27 2006-03-09 Elan Pharmaceuticals, Inc. Methods of treatment of amyloidosis using ethanol cyclicamine derivatives aspartyl protease inhibitors
WO2006052691A2 (en) * 2004-11-05 2006-05-18 Wyeth Pet and magnetic resonance for screening alzheimer's disease therapeutics
PE20061329A1 (en) 2004-12-15 2006-12-08 Neuralab Ltd HUMANIZED AB ANTIBODIES TO IMPROVE COGNITION
EP2529619B1 (en) 2005-02-17 2015-09-23 Biogen MA Inc. Treating neurological disorders
JP4853892B2 (en) * 2005-04-13 2012-01-11 独立行政法人国立精神・神経医療研究センター Method for evaluating specific RNAi for mutant allele
AU2006244014B2 (en) 2005-05-10 2011-03-17 Biogen Ma Inc. Treating and evaluating inflammatory disorders
GB0511861D0 (en) * 2005-06-13 2005-07-20 Merck Sharp & Dohme Proteins
EP1746092A1 (en) 2005-07-22 2007-01-24 Exonhit Therapeutics SA Compounds and methods for treatment of amyloid-B-peptide related disorders
CA2617294A1 (en) * 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Substituted ethane-1,2-diamines for the treatment of alzheimer's disease ii
CA2618019A1 (en) * 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Compounds for the treatment of alzheimer's disease
CA2618474A1 (en) * 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Compounds for treating alzheimer's disease
US20100144681A1 (en) * 2005-08-11 2010-06-10 Klaus Fuchs Compounds for the treatment of alzheimer's disease
WO2007017507A1 (en) * 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Beta-secretase inhibitors for use in the treatment of alzheimer's disease
EP1937638A1 (en) * 2005-10-12 2008-07-02 Elan Pharmaceuticals Inc. Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors
WO2007047305A1 (en) * 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
WO2007092839A2 (en) * 2006-02-06 2007-08-16 Janssen Pharmaceutica N.V. Macrocycle derivatives useful as inhibitors of beta-secretase (bace)
WO2007092846A2 (en) * 2006-02-06 2007-08-16 Janssen Pharmaceutica N.V. 2-AMINO-3,4-DIHYDRO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
WO2007092854A2 (en) 2006-02-06 2007-08-16 Janssen Pharmaceutica N.V. 2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2008042024A2 (en) 2006-06-01 2008-04-10 Elan Pharmaceuticals, Inc. Neuroactive fragments of app
EP2041270B1 (en) 2006-07-13 2013-11-20 Wyeth LLC Production of glycoproteins
EP2089417B1 (en) 2006-10-12 2014-12-31 BHI Limited Partnership Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
WO2008055260A2 (en) 2006-11-03 2008-05-08 Wyeth Glycolysis-inhibiting substances in cell culture
DK2115126T3 (en) 2007-03-02 2015-05-04 Wyeth Llc Use of copper and glutamate in cell culture for the preparation of polypeptides
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US8466118B2 (en) * 2007-04-23 2013-06-18 Saint Louis University Modulation of blood brain barrier protein expression
EA200971050A1 (en) 2007-05-11 2010-06-30 Томас Джефферсон Юниверсити METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS
EP2164834A2 (en) 2007-07-06 2010-03-24 Boehringer Ingelheim International GmbH Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture
SI2182983T1 (en) 2007-07-27 2014-09-30 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases with humanised anti-abeta antibodies
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
ES2400173T3 (en) * 2008-01-28 2013-04-08 Janssen Pharmaceutica Nv 6-Substituted thio-2-amino-quinoline derivatives useful as beta-secretase inhibitors (BACE)
AU2009209147B2 (en) * 2008-01-29 2013-03-14 Janssen Pharmaceutica Nv 2-amino-quinoline derivatives useful as inhibitors of beta-secretase (BACE)
JP2011514158A (en) * 2008-02-19 2011-05-06 エダン・バイオテクノロジー・インコーポレイテッド Antisense regulation of amyloid beta protein expression
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US20110023152A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of cognition related genes in animals
DK2605655T3 (en) 2010-08-19 2019-02-04 Buck Institute For Age Res METHODS OF TREATING SMALL COGNITIVE DISABILITY (MCI) AND RELATED DISORDERS
CN104270945B (en) 2012-03-19 2017-03-29 巴克老龄化研究所 APP specific b ACE inhibitor (ASBI) and application thereof
DK2864360T3 (en) 2012-06-25 2017-12-18 Brigham & Womens Hospital Inc TARGETED THERAPY
KR102220259B1 (en) 2013-02-12 2021-02-25 버크 인스티튜트 포 리서치 온 에이징 Hydantoins that modulate bace-mediated app processing
EP3708184A1 (en) 2013-03-27 2020-09-16 The General Hospital Corporation Methods and agents for treating alzheimer s disease
KR101890978B1 (en) 2014-06-17 2018-08-24 서울대학교산학협력단 Transgenic cloned porcine Models for alzheimer's disease and the Use thereof
US11168369B2 (en) 2014-11-25 2021-11-09 The Brigham And Women's Hospital, Inc. Method of identifying and treating a person having a predisposition to or afflicted with a cardiometabolic disease
US10683552B2 (en) 2014-11-25 2020-06-16 Presidents And Fellows Of Harvard College Clonal haematopoiesis
AU2016311502B2 (en) 2015-08-27 2019-07-18 Nantneuro, Llc Compositions for app-selective bace inhibition and uses therfor
EP3455223B1 (en) 2016-05-12 2023-11-08 Buck Institute for Research on Aging Compounds to promote normal processing of app

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4492760A (en) * 1983-04-19 1985-01-08 The Wistar Institute Of Anatomy And Biology HLA D Typing assay
JPS6147500A (en) * 1984-08-15 1986-03-07 Res Dev Corp Of Japan Chimera monoclonal antibody and its preparation
EP0173494A3 (en) * 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) * 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (en) * 1984-12-04 1986-06-21 Teijin Ltd Expression of hybrid antibody gene
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
JPS62100291A (en) * 1985-10-28 1987-05-09 Teijin Ltd Gene fragment and plasmid
DE3689123T2 (en) * 1985-11-01 1994-03-03 Xoma Corp MODULAR UNIT OF ANTIBODY GENES, ANTIBODIES MADE THEREOF AND USE.
DE3702789A1 (en) * 1987-01-30 1988-08-18 Bayer Ag PROCUREMENT PROTEIN OF APC POLYPEPTIDE, FOR CODING DNA AND DIAGNOSTIC USE OF DNA AND PROTEIN
WO1989006689A1 (en) * 1988-01-13 1989-07-27 The Mclean Hospital Corporation Genetic constructs containing the alzheimer brain amyloid gene
US5134062A (en) * 1988-03-22 1992-07-28 Cornell Research Foundation, Inc. Diagnosis of neuronal disorders and screening potential therapeutic agents therefor
DE3907562A1 (en) 1989-03-09 1990-09-13 Bayer Ag ANTISENSE OLIGONUCLEOTIDS FOR INHIBITING THE TRANSACTIVATOR TARGET SEQUENCE (TAR) AND THE SYNTHESIS OF THE TRANSACTIVATOR PROTEIN (TAT) FROM HIV-1 AND THE USE THEREOF
JPH04505261A (en) 1989-05-10 1992-09-17 スローン―ケツテリング・インステイテユート・フオー・キヤンサー・リサーチ Stably transformed eukaryotic cells containing transcribable foreign DNA under the control of a Pol III promoter
US5234814A (en) * 1989-06-01 1993-08-10 Du Pont Merck Pharmaceutical Company Diagnostic assay for alzheimer's disease
WO1991004753A1 (en) 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof
US5180819A (en) 1989-12-22 1993-01-19 The Trustees Of Columbia University In The City Of New York Purified myeloblastin, nucleic acid molecule encoding same, and uses thereof
EP0451700A1 (en) * 1990-04-10 1991-10-16 Miles Inc. Recombinant APP minigenes for expression in transgenic mice as models for Alzheimers's disease
WO1991016628A1 (en) * 1990-04-24 1991-10-31 The Regents Of The University Of California Purification, detection and methods of use of protease nexin-2
AU646877B2 (en) * 1990-06-15 1994-03-10 Scios Nova Inc. Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease
WO1992000521A1 (en) * 1990-06-29 1992-01-09 Case Western Reserve University Diagnostic and prognostic methods based on soluble derivatives of the beta amyloid protein precursor
US5200339A (en) * 1990-08-17 1993-04-06 Abraham Carmela R Proteases causing abnormal degradation of amyloid β-protein precursor
BE1003316A5 (en) * 1990-11-27 1992-02-25 Will L F & Cie Sa MONOCLONAL ANTIBODY USEFUL FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE, SECRETARY HYBRIDOMA OF SUCH A MONOCLONAL ANTIBODY AND PROCESS FOR PREPARING THE SAME.
ES2335720T3 (en) 1991-01-21 2010-03-31 Elan Pharmaceuticals, Inc. TEST AND MODEL FOR ALZHEIMER'S DISEASE.
AU2765992A (en) * 1991-10-03 1993-05-03 Indiana University Foundation Method for screening for alzheimer's disease
EP0620849B1 (en) * 1992-01-07 2003-06-25 Elan Pharmaceuticals, Inc. Transgenic animal models for alzheimer's disease
US5604102A (en) * 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US7371129B2 (en) 2005-04-27 2008-05-13 Samtec, Inc. Elevated height electrical connector

Also Published As

Publication number Publication date
CA2372251A1 (en) 1992-08-06
JP3510244B2 (en) 2004-03-22
ATE286971T1 (en) 2005-01-15
DE69233468D1 (en) 2005-02-17
ES2236682T5 (en) 2011-03-31
JP2004261187A (en) 2004-09-24
DE69233468T3 (en) 2011-05-05
DK0568575T4 (en) 2010-12-20
JP3574432B2 (en) 2004-10-06
JPH06504441A (en) 1994-05-26
US5877015A (en) 1999-03-02
DK0568575T3 (en) 2005-05-23
EP0971033A2 (en) 2000-01-12
EP0971033A3 (en) 2003-11-12
ES2335720T3 (en) 2010-03-31
EP0568575B1 (en) 2005-01-12
CA2101774C (en) 2011-01-04
ATE447016T1 (en) 2009-11-15
DE971033T1 (en) 2001-05-03
US6300540B1 (en) 2001-10-09
DE69233774D1 (en) 2009-12-10
EP0568575B2 (en) 2010-11-03
JP2002306195A (en) 2002-10-22
EP0568575A1 (en) 1993-11-10
ES2236682T3 (en) 2005-07-16
DK0971033T3 (en) 2009-12-14
DE69233468T2 (en) 2005-12-22
AU1169492A (en) 1992-08-27
US20030165958A1 (en) 2003-09-04
WO1992013069A1 (en) 1992-08-06
EP0971033B1 (en) 2009-10-28
AU652997B2 (en) 1994-09-15

Similar Documents

Publication Publication Date Title
CA2101774A1 (en) Test and model for alzheimer's disease
US20180010190A1 (en) Genetic variant of the annexin a5 gene
US20040132021A1 (en) Osteolevin gene polymorphisms
US6623927B1 (en) Method of detection of allelic variants of SCA2 gene
Bisceglia et al. Molecular analysis of the cystinuria disease gene: identification of four new mutations, one large deletion, and one polymorphism
EP0812922A2 (en) Polymorphisms in human mitochondrial nucleic acid
WO1997003999A1 (en) Mutant s182 genes
JP2003513620A (en) Molecular structure of RHD negative locus
JPH05211897A (en) Nucleotide sequence
EP0970243B1 (en) Diagnosis and treatment of glaucoma
EP0627011A1 (en) Myotonic dystrophy.
US7001720B1 (en) Cloning of a gene mutation for parkinson's disease
AU2001239837B2 (en) Methods and composition for diagnosing and treating pseudoxanthoma elasticum and related conditions
EP0811695A2 (en) Mutant S182(PS-1) genes
CA2425669C (en) Mutations in the ferroportin 1 gene associated with hereditary haemochromatosis
US5830661A (en) Diagnosis and treatment of glaucoma
EP1641937B1 (en) Mutations in the slc40a1 gene associated to impaired iron homeostasis
AU761135B2 (en) Diagnosis of glaucoma
US7339049B1 (en) Polymorphisms in human mitochondrial DNA
HUE025558T2 (en) Method of determining the genotype relating to hereditary nasal parakeratosis (HNPK) and nucleic acids usable in said method
CA2235611A1 (en) Method to detect polymorphism in the s182 gene
Scott 11 New horizons in lipoprotein research
US20030207272A1 (en) Composition and methods for detection of von willebrand's disease
WO2001077178A2 (en) Compositions and methods for detection of von willebrand's disease
WO2000063436A1 (en) Disease reversing targets

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry